Dulaglutide

Type 2 Diabetes Management

Dulaglutide is primarily prescribed to help control blood sugar levels in adults and children 10 years of age and older who have type 2 diabetes. It is intended to be used in combination with a healthy diet and regular exercise program to improve glycemic control.

Cardiovascular Risk Reduction

In addition to managing blood sugar, dulaglutide is used in adults with type 2 diabetes to lower the risk of serious cardiovascular problems, such as:

• Heart attack
• Stroke
• Death related to heart or blood vessel disease

This use is specifically for adults who already have established heart disease or who are at an increased risk for developing heart problems due to multiple risk factors.

Important Limitations

Dulaglutide is not used to treat type 1 diabetes, a condition where the body does not produce insulin. It is also not intended for the treatment of diabetic ketoacidosis, a serious complication of diabetes involving high levels of blood acids called ketones. It is generally not the first medication recommended for people whose diabetes is well-controlled by diet and exercise alone.

Mechanism of Action

Dulaglutide works by acting like a hormone naturally produced in the body called glucagon-like peptide-1 (GLP-1). This hormone is part of a group called incretins, which are released from the intestines in response to food intake.

This medication helps control blood sugar in several ways:

• Stimulating Insulin Release: When blood sugar levels are high, dulaglutide signals the pancreas to release insulin. Insulin is the hormone responsible for moving sugar out of the bloodstream and into the body's cells to be used for energy.
• Reducing Liver Sugar Production: It helps prevent the liver from making and releasing too much extra sugar into the blood by suppressing a hormone called glucagon.
• Slowing Gastric Emptying: It slows down the speed at which food leaves the stomach. By slowing digestion, the medication helps prevent sharp spikes in blood sugar levels immediately after a meal.

Because dulaglutide depends on the presence of high blood sugar to trigger insulin release, it is less likely to cause dangerously low blood sugar (hypoglycemia) when used as a standalone treatment compared to some other diabetes medications. It is specifically used for type 2 diabetes, where the body still produces some insulin but does not use it effectively.

Common Side Effects

The most frequently reported side effects of dulaglutide involve the digestive system. These symptoms are often most noticeable when starting the medication or increasing the dose. Common side effects include:

• Nausea and vomiting
• Diarrhea
• Abdominal pain
• Decreased appetite
• Indigestion or upset stomach
• Constipation
• Fatigue

Serious Side Effects

Some side effects can be serious. Seek medical help immediately if you experience any of the following:

• Persistent, severe pain in the upper abdomen that may radiate to the back, with or without vomiting (potential signs of pancreatitis)
• Signs of kidney problems, such as decreased urination or swelling in the legs and ankles
• Gallbladder problems, which may cause fever and pain in the upper right stomach area
• Severe allergic reactions, including hives, swelling of the face or throat, and difficulty breathing
• Changes in vision

Dulaglutide may also cause low blood sugar (hypoglycemia), especially when taken with other medications for diabetes like insulin or sulfonylureas. Symptoms of low blood sugar can include shakiness, sweating, fast heartbeat, and blurred vision.

Boxed Warning: Thyroid Tumors

In animal studies, dulaglutide caused thyroid C-cell tumors. It is not known if it causes these tumors or medullary thyroid carcinoma (MTC) in humans. This medication is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis

There have been reports of acute pancreatitis in patients using dulaglutide. Signs of pancreatitis include persistent, severe abdominal pain that may radiate to the back. If pancreatitis is suspected, the medication should be discontinued promptly.

Kidney Function and Dehydration

Gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, may lead to dehydration. This fluid loss can cause acute kidney injury or worsening of chronic renal failure. Monitoring of renal function is recommended for patients experiencing severe gastrointestinal effects.

Hypoglycemia

Using dulaglutide in combination with insulin secretagogues (such as sulfonylureas) or insulin increases the risk of hypoglycemia (low blood sugar). A lower dose of the concomitant medication may be required to reduce this risk.

Additional Warnings

• Hypersensitivity: Serious allergic reactions, including anaphylaxis and angioedema, have been reported.
• Diabetic Retinopathy: Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
• Severe Gastrointestinal Disease: Dulaglutide has not been studied in patients with severe gastrointestinal disease, including gastroparesis, and is not recommended for these individuals.
• Gallbladder Disease: Acute gallbladder disease, such as gallstones or cholecystitis, has occurred in clinical trials.

Pregnancy

There is limited information regarding the safety of dulaglutide use during pregnancy. Animal studies have indicated potential risks to the fetus, though it is unclear if these effects occur in humans. Because dulaglutide remains in the system for several weeks, it is often recommended to stop using the medication at least two months before trying to become pregnant.

If you are pregnant or planning to become pregnant, discuss blood sugar management options with your doctor. Maintaining stable blood glucose levels is important during pregnancy, and alternative treatments may be suggested.

Breastfeeding

It is not known if dulaglutide passes into breast milk or how it might affect a nursing child. Because many medications can be excreted in human milk, caution is advised. Patients should consult with their healthcare provider to weigh the benefits of breastfeeding against the potential risks of the medication to the infant.

Available Forms

Dulaglutide is supplied as a sterile solution for subcutaneous injection. It is available in the following form:

• Pre-filled pen: A disposable delivery device containing the medication, designed for administration under the skin.

The solution is clear and colorless. Each pen is intended for single use and should be disposed of in a puncture-resistant container after the dose is delivered.

FDA Approval and Indications

Dulaglutide was first approved by the U.S. Food and Drug Administration (FDA) in 2014. It is currently approved for the following indications:

• Glycemic Control: To improve blood sugar levels in adults and children 10 years of age and older with type 2 diabetes, when used alongside diet and exercise.
• Cardiovascular Risk Reduction: To reduce the risk of major adverse cardiovascular events, such as heart attack or stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Dulaglutide is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

Boxed Warning

The FDA has issued a boxed warning for dulaglutide due to the risk of thyroid C-cell tumors. In animal studies, dulaglutide caused an increased incidence of thyroid tumors, though it is unknown if it causes these tumors in humans. Because of this potential risk, the medication is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Safety Communications

The FDA monitors the safety of approved medications through the Adverse Event Reporting System (FAERS). In 2020, the FDA identified a potential signal of serious risk for intestinal obstruction (ileus) associated with the class of medications known as GLP-1 receptor agonists, which includes dulaglutide. The FDA continues to evaluate these reports to determine if further regulatory action or labeling changes are required.

How Dulaglutide Affects Weight

Dulaglutide belongs to a class of drugs called GLP-1 receptor agonists. While its primary purpose is to manage blood sugar levels in adults with type 2 diabetes, many people experience weight loss while taking it. This occurs because the medication mimics a natural hormone in the body that performs several functions:

• Slowing digestion: It delays gastric emptying, which means food stays in the stomach longer, helping you feel full for a more extended period.
• Appetite regulation: It acts on areas of the brain that control hunger and satiety, often leading to reduced food intake.

FDA Approval and Use

Dulaglutide is not FDA-approved as a weight-loss medication. It is approved for improving blood sugar control in people with type 2 diabetes and for reducing the risk of major cardiovascular events in certain adults with type 2 diabetes. Because it is not a primary treatment for obesity, weight loss is considered a secondary effect. Results are most consistent when the medication is used alongside a healthy diet and regular exercise.